Revised 4/10/2013

Department of Veteran Affairs Department of Defense

Veterans Health Administration U.S. Army Medical Command

### Washington, DC 20420 Quality Management

**Fort Sam Houston, TX 78234**

#### GUIDELINE FOR GUIDELINES

A. Guideline Development and Approval Process:

**1. New Guideline Idea:** When a clinician or other group wants to develop a VA/DoD guideline,

* An application is completed and submitted to VA/DoD Evidence Based Practice Work Group (EBPWG) through the submitter’s respective VACO/MEDCOM Evidence Based Practice discipline office.
  + At a minimum the application will include a description of the guideline,
  + Identify end-users of the guideline and perceived gaps in care and/or
  + Identify changes in performance to be driven by the guideline. (See Attachment I: Application Form)
  + To the extent possible, data substantiating the need for the guideline will be presented.
* The applicant will also submit a brief structured review of the literature.
* The VA/DoD Evidence-Based Practice Work Group may also suggest topics/areas for guideline development, particularly as they relate to the frequency of occurrence and uniqueness of our military and veteran population.

1. **Evidence Based Practice Work Group Prioritization Subgroup Reviews & Prioritizes Applications:** Upon receipt of the application, the EBPWG Prioritization Subgroup will review the application and prioritize it for development and implementation in VA and DoD.

* Within 1 week of receipt the EBPWG Prioritization Subgroup will acknowledge receipt of each application.
* The EBPWG Prioritization Subgroup will consider the following issues:
  + High incidence or prevalence,
  + Risk and cost of the disease or condition in the general veteran/military population or sub-populations targeted by Special Emphasis Programs.
  + Potential for reduction of clinically significant variations in the prevention, diagnosis, treatment, or clinical management of a disease or condition will also be considered when establishing priorities.
* The Prioritization Subgroup will notify the applicant of the outcome of the review generally within 4 weeks of receipt.

**3. Designees of the DoD and the VA Offices of Quality, Safety & Value and VA Patient Care Services Identify Clinical Champions, and /or EBPWG Representative:** When a topic has been approved for guideline development, the DoD representatives, Offices of Quality, Safety & Value, and Patient Care Services will:

* Identify clinical leaders who will champion the guideline development and dissemination initiative at the national VA and DoD Health Care Systems levels.
* Assure there is representation from primary care and specialty services.
* Invite members of related VA QUERI (Quality Enhancement Research Initiative) groups to participate, if available.
* An Evidence Chaperone from the Evidence Based Practice Program office and/or EBPWG member will be assigned as needed to guide the integrity of the evidence process.
* Assign a representative from the EBPWG to monitor the development process.

**4. Pre-Planning Conference:**

The DoD and the VA Offices of Quality, Safety & Value and Patient Care Services, in collaboration with Employee Education System, will convene a face-to-face pre-planning conference or teleconference with the identified champion(s) and other key clinical leaders in order to train champions regarding the evidence-based approach and process. At a minimum, the pre-planning conference/teleconference should accomplish the following:

* Identify the end users of the guideline.
* Define the scope of the Guideline Initiative.
* Identify seed/reference guidelines, if any.
* Specify representation from appropriate clinical specialties to be involved with the guideline development.
* Project timelines for each phase of guideline development.
* Disclose any areas of potential conflict of interest.
* Assign senior champions for each module.
* Develop a production schedule for each module.
* Specify which modules can be fast-tracked for distribution prior to publication of the comprehensive guideline.
* Identify approaches that will ensure VA and DoD collaboration and partnership with the broader community.
* Define responsibilities of champions and participants.

**5. Small Group of Champion(s) and Other Key Clinical Leaders are Assembled:**

* VA and DOD Champions and other key clinical leaders meet face-to-face/teleconference, as needed, with the facilitator to identify key questions formulated in the PICO(TS)
* **P**opulation – Characteristics of the target patient population
* **I**ntervention – Exposure, diagnostic, or prognosis
* **C**omparison – Intervention, exposure, or control used for comparison
* **O**utcome – Outcomes of interest to be answered by the evidence
* **T**ime (if applicable)- Describes the duration of time that is of interest
* **S**etting (if applicable) – Describes the setting or context of interest

* This is an iterative process and may require discussions on conference calls to complete the task.
* During this iterative process it may be determined that a clinical practice guideline (CPG) currently exists for the proposed topic. If appropriate the Champions will utilize the Adaptation Process, identified in step 9.
* Boundaries for admissible evidence should also be set. For example, questions of the efficacy of interventions usually means that randomized controlled trials should be sought, while questions of risk usually mean that prospective cohort studies should be sought.
* Evidence-based bullets for immediate publication should also be identified.
* **Potential Conflicts of Interest: The VA/DoD has adopted a policy of transparency, disclosing potential conflicts and competing interests of all individuals who participate in the development, revision, and review of the VA/DoD clinical practice guidelines.** Champion(s) and other key clinical leaders involved with this effort will be asked to submit disclosure statements to reveal any areas of potential conflict of interest (See Attachment II) for the preceding 12 months.
  + 1. Disclosures of conflict of interest verbal affirmations are conducted at each meeting, and a signed disclosure statement is required annually.
    2. Members may be subject to random web based surveillance (i.e ProPublica).
    3. If there is a positive (yes) conflict of interest response (actual or potential) then a determination is made by the co**-**chairs and evidence based practice program office based on level and extent of involvement to mitigate conflict of interest. Determination may range from restricting participation and/or voting on section related to conflict, up to removal from the work group. Recusals are determined by the individual, co**-**chairs and evidence based practice office.
    4. Co-chairs and evidence based practice program office is responsible for monitoring conflict of interest compliance.
* Once the Scope of the Guideline is agreed on by the Co-Chairs and other key leaders, it is sent for review and approval by the VA/DoD EBPWG membership. On approval by the VA/DoD EBPWG, the guideline workgroup can begin.

**6. Conference Call among Champions and EBPWG Representative is conducted:**

* When the questions have been developed, the group will convene via conference calls to:
* review the questions to assure that they are on track and
* address the questions that will lead to a comprehensive, systematic review of the literature pertaining to the topic.
* When the evidence reviews are completed, the questions and the reviews will be posted on the work group web.
* However, prior to posting the reviews, the facilitator, Champion, (and the Evidence Chaperone as needed), will convene to ensure the adequacy of the evidence reviews.

7. Systematic Review of the Literature Based on the Questions Identified in Step Five is Conducted & Tables of Evidence are Produced:

* A systematic review of the literature, by a disinterested party, will be performed to minimize bias, collect all appropriate evidence available, and assess its potential applicability to the clinical question under consideration.
* The Champions (and Evidence Chaperone as needed) will work with staff from the Evidence Center to ensure conformity to prevailing standards for conducting high-quality systematic literature reviews.
  + The first step in gathering the evidence is to see if a suitable, recent systematic review has already been published.
  + If a current systematic review is not available, an original systematic review will be done using an established protocol, such as those of the Cochrane Collaboration, Evidence Synthesis Program, or the US Preventive Services Task Force (USPSTF).
* At a minimum, systematic reviews will use explicit, reproducible methods to
  + identify relevant, eligible studies
  + assess the quality of each study and the body of evidence
  + critically appraise key studies and
  + synthesize results.
* To grade the quality of individual studies, the reviews will apply the USPSTF or GRADE criteria for quality (Harris, Helfand, & Woolf, 2001) adapting those to specific clinical areas.

8. A Group of Clinical Experts is Convened to Develop the Guideline: Once the evidence tables have been developed,

* A group of not more than 15-20 experts and other key clinical leaders will be identified and convened to evaluate the evidence and develop the guideline in accordance with it.
* In advance of the meeting, each participant will be asked to submit a disclosure statement regarding any potential conflicts of interest. These will be reviewed in advance to assure balance in the group that is forming.
* Each meeting will begin with a brief session that will permit full disclosure to the group any conflicts related to the guideline
* Key points of the guideline will be identified.
* A facilitator will ensure that the meeting stays focused and that the evidence remains the driving force behind the guidelines.
* Most guidelines will be represented in an algorithmic format outlining step-by-step decision points in the disease management process.
* The strength of recommendation and quality of evidence are provided at the end of each annotation in the guideline.
* The systematic review will summarize the quality and consistency of the evidence and the magnitude of benefits and harms.
* To make the actual recommendations, the clinical experts, led by the designated VA/DoD Champions, will
  + interpret the evidence,
  + assess its ability to be applied in the clinical setting and its applicability to the population of interest, and
  + assess the overall strength of evidence for the recommendation.
* Recommendations based solely on clinical judgment and experience will be thoroughly scrutinized to eliminate bias and self-interest.
* This group of clinical experts will also develop consensus-based recommendations as needed when there is inadequate evidence.

Currently, the clinical experts will grade recommendations using the USPSTF system, A transition to the GRADE system is being considered.

8a. The USPSTF system is described in USPSTF Methods and Process, August 2012, http://www.uspreventiveservicestaskforce.org/methods.htm. In this system, the grade for the strength of a recommendation depends on the overall quality of evidence and on the magnitude of net benefit. Clinical experts will:

1. Rate the overall quality of the evidence using the terms shown in Table 1.
2. Rate the net benefit (benefits minus harms) “substantial,” “moderate,” “small,” or “zero or negative” as described in Table 2.
3. Based on these ratings of the overall quality of the evidence and the magnitude of net benefit, the clinical experts will assign a grade to each recommendation using the definitions in Tables 3 and 4.

* Consistent results from a number of higher-level studies [LE] (see Table 1) that have been conducted across a broad range of populations support a high degree of certainty that the results of the studies are true. In such case the entire body of evidence would be considered ‘‘good” quality.
* The overall strength of each body of evidence that addresses a particular Key Question is then assessed. The number, quality, and size of the studies, as well as the consistency of results between studies and the directness of the evidence will be considered in assigning an overall quality[QE] of the evidence (i.e., good, fair, or poor) (see Table 2). The quality of the body of evidence is considered ‘fair” when the results could be due to true effects or to biases present across some or all of the studies. For a ‘‘poor” quality body of evidence, any conclusion is uncertain due to serious methodological shortcomings, sparse data, or inconsistent results. For interventions that were supported by studies of ‘Fair’ or “Good” quality, the clinical experts evaluate the benefits and the potential harms as demonstrated by the results of the studies.
* In the final step, the Strength of Recommendation [SR] is determined based on the Quality of the Evidence [QE], and the clinical significance of the Net Benefit [NE] (see Table 3) for each intervention. Thus, the grade (i.e., A, B, C, D or I) assigned to guideline recommendations reflects both the Quality of the evidence and the potential clinical benefit that the intervention may provide to patients (see Table 4).

|  |  |
| --- | --- |
| **Table 1: Level of Evidence (LE)** | |
| **I** | At least one properly done RCT |
| **II-1** | Well-designed controlled trial without randomization |
| **II-2** | Well-designed cohort or case-control analytic study, preferably from more than one source |
| **II-3** | Multiple time series evidence with/without intervention, dramatic results of uncontrolled experiment |
| **III** | Opinion of respected authorities, descriptive studies, case reports, and expert committees |

|  |  |
| --- | --- |
| **Table 2: Overall Quality [QE]** | |
| **Good** | High grade evidence (I or II-1) directly linked to health outcome |
| **Fair** | High grade evidence (I or II-1) linked to intermediate outcome; *or* Moderate grade evidence (II-2 or II-3) directly linked to health outcome |
| **Poor** | Level III evidence or no linkage of evidence to health outcome |

|  |  |
| --- | --- |
| **Table 3: Net Effect of the Intervention [NE]** | |
| **Substantial** | More than a small relative impact on a frequent condition with a substantial burden of suffering;  *Or*  A large impact on an infrequent condition with a significant impact on the individual patient level. |
| **Moderate** | A small relative impact on a frequent condition with a substantial burden of suffering;  or  A moderate impact on an infrequent condition with a significant impact on the individual patient level. |
| **Small** | A negligible relative impact on a frequent condition with a substantial burden of suffering;  *Or*  A small impact on an infrequent condition with a significant impact on the individual patient level. |
| **Zero or Negative** | Negative impact on patients;  *or*  No relative impact on either a frequent condition with a substantial burden of suffering, or an infrequent condition with a significant impact on the individual patient level. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 4: Final Grade of Strength of Recommendation [SR]** | | | | |
|  | *The net benefit of the intervention* | | | |
| ***Quality of Evidence*** | **Substantial** | **Moderate** | **Small** | **Zero or Negative** |
| ***Good*** | A | B | C | D |
| ***Fair*** | B | B | C | D |
| ***Poor*** | I | I | I | I |

|  |  |
| --- | --- |
| **Strength of Recommendation [SR]** | |
| SR |  |
| A | A strong recommendation that the clinicians provide the intervention to eligible patients.  *Good evidence was found that the intervention improves important health outcomes and concludes that benefits substantially outweigh harm.* |
| B | A recommendation that clinicians provide (the service) to eligible patients.  *At least fair evidence was found that the intervention improves health outcomes and concludes that benefits outweigh harm.* |
| C | No recommendation for or against the routine provision of the intervention is made.  *At least fair evidence was found that the intervention can improve health outcomes, but concludes that the balance of benefits and harms is too close to justify a general recommendation.* |
| D | Recommendation is made against routinely providing the intervention to asymptomatic patients.  *At least fair evidence was found that the intervention is ineffective or that harms outweigh benefits.* |
| I | The conclusion is that the evidence is insufficient to recommend for or against routinely providing the intervention.  *Evidence that the intervention is effective is lacking, or poor quality, or conflicting, and the balance of benefits and harms cannot be determined.* |

\*USPSTF Methods and Process.

http://www.uspreventiveservicestaskforce.org/methods.htm, August 2012.

Evidence-based Practice Centers Overview. November 2012. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/epc/

**The GRADE system is described in the series of tables below;**

The GRADE system incorporates two types of ratings:

* Quality of the evidence for a single outcome for a single comparison (High, Moderate, Low, or Very Low)
* Strength of recommendation for the technology (Strong, Weak, or No recommendation



Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y. Alonso-Coello, P. Schünemann, H. J. & the GRADE Working Group. (2008). GRADE: going from evidence to recommendations. *BMJ, 336*, 1049-1051.



Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y. Alonso-Coello, P. Schünemann, H. J. & the GRADE Working Group. (2008). GRADE: going from evidence to recommendations. *BMJ, 336*, 1049-1051.

**“Box 2 | Quality of evidence and definitions”**

|  |
| --- |
| **“High quality**— Further research is very unlikely to change our confidence in the estimate of effect |
| **Moderate quality**— Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate |
| **Low quality**— Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate |
| **Very low quality**— Any estimate of effect is very uncertain” |

From: Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y. Alonso-Coello, P. Schünemann, H. J. & the GRADE Working Group. (2008). GRADE; An emerging concensus on rating quality of evidence and strength of recommendations. *BMJ, 336*, 924-926.

**“Box 2: Criteria for assigning grade of evidence: Type of evidence “**

|  |
| --- |
| “Randomised trial = high  Observational study = low  Any other evidence = very low |
| Decrease grade if:  • Serious ( − 1) or very serious ( − 2) limitation to study quality  • Important inconsistency ( − 1)  • Some ( − 1) or major ( − 2) uncertainty about directness  • Imprecise or sparse data ( − 1)  • High probability of reporting bias ( − 1)  Increase grade if:  • Strong evidence of association—significant relative risk of > 2 ( < 0.5) based on consistent evidence from two or more observational studies, with no plausible confounders (+1)46  • Very strong evidence of association—significant relative risk of > 5 ( < 0.2) based on direct evidence with no major threats to validity (+2)   * Evidence of a dose response gradient (+1)   • All plausible confounders would have reduced the effect (+1)” |

Grade Working Group. (2004). Grading the quality of evidence and strength of recommendations. *BMJ,* 328.

**“Box 3: Imprecise or sparse data”**

|  |
| --- |
| “There is not an empirical basis for defining imprecise or sparse data. Two possible definitions are:  • Data are sparse if the results include just a few events or observations and they are uninformative  • Data are imprecise if the confidence intervals are sufficiently wide that an estimate is consistent with either important harms or important benefits  These different definitions can result in different judgments. Although it may not be possible to reconcile these differences, we offer the following guidance when considering whether to downgrade the quality of evidence due to imprecise or sparse data:  • The threshold for considering data imprecise or sparse should be lower when there is only one study. A single study with a small sample size (or few events) yielding wide confidence intervals spanning both the potential for harm and benefit should be  considered as imprecise or sparse data  • Confidence intervals that are sufficiently wide that, irrespective of other outcomes, the estimate is consistent with conflicting recommendations should be considered as imprecise or sparse data” |

Grade Working Group. (2004). Grading the quality of evidence and strength of recommendations. *BMJ,* 328.

A computer program exists to assist in developing GRADE recommendations:

Brozek, J., Oxman, A., Schünemann, H. (2008). GRADEpro. [Computer program]. Version 3.2 for Windows. <http://www.ims.cochrane.org/revman/other-resources/gradepro> .

**9.** **Guideline Adaptation**

The overall objective of adaptation is to take advantage of existing guidelines in order to enhance the efficient production and use of high quality adapted guidelines. Cultural and organizational differences can lead to legitimate variations in recommendations, even when the evidence base is the same. However, with a systematic approach to guideline modification adaptations can be used as an alternative to *de novo* guideline development. Adaptation of an existing guideline should ensure the validity of the resulting recommendations.

* The adaptation process is based on the following core principles:

Respect for the evidence based principles of guideline development

Reliable and consistent methods to ensure quality of the adapted guideline

Participative approach involving key stakeholders, to foster acceptance

and ownership of the adapted guideline

Explicit consideration of context during adaptation to ensure

organizational relevance for practice

Transparent reporting to promote confidence in the recommendations of

the adapted guideline

Format consistent with VA/DoD guideline development

Accountability to the primary guideline sources

* A panel of at least four members including the VA/DoD CPG Work group Champions, will utilize the GRADE II Instrument ([www.agreetrust.org](http://www.agreetrust.org)) to assess the quality of the proposed CPG and adaptability for VA/DoD specific population use.
* Following the consensus process the panel, along with a facilitator, may decide along the following:

1. Reject the whole guideline: After reviewing all of the assessments, the panel decides to reject the complete guideline. The decision should be on how the panel weighs the assessment (e.g. poor AGREE scores, guideline is out of date, or the recommendations do not apply to the panels context).
2. Accept a whole guideline and all of its recommendations: After reviewing all of the assessments, the panel accepts the guideline as is.
3. Accept specific recommendations: After reviewing the recommendations from the guideline the panel decides which recommendations to accept and which to reject (e.g. those recommendations needing major modification would be rejected).
4. Modify specific recommendations: After reviewing the recommendations from the guideline, the panel decides which are acceptable but need to be modified (e.g. new data may be added to the original recommendation or the wording might be changed to better reflect the panel’s context). (ADAPTE Collaboration, 2009)

* Care must always be taken when modifying existing guidelines and/or recommendations not to change the recommendations to such an extent that they are no longer in keeping with the evidence upon which they should be based.
* Based on the above decisions, the panel can create an adapted guideline acceptable for VA/DoD specific clinical practice guidelines. Note: All adapted guidelines shall conform to the VA/DOD CPG standard to include algorithmic format. Adapted guidelines follow the same VA/DoD CPG process as identified from step 10 forward.

**10. Follow Up Conference Calls will be Conducted to Discuss Unresolved Issues and Compile the Annotations of the Guideline.**

* The resulting product is the first draft of the guideline that will be distributed.
* Prior to this review, the Champions and the Facilitator to confirm the timeline and assure that the recommendations are consistent with the evidence.

11. The First Draft of the Guideline will be posted on a Development Website for Field Review and Public Comment:

* + DoD Evidence-based Practice Division, Patient Care Services and the VA Network Clinical Managers will solicit feedback from a broader group of end users, to include patients.
  + VA Network designated staff and DoD end users will be asked to review the guideline and provide feedback to the Guideline Champions and/or directly to the guideline development experts via the wiki web page which is available for online comment. This portion of the field test is more specifically **directed towards an evaluation of the content and the logic and flow of the guideline**.
* Comments and recommendations regarding proposed changes to the content of the guideline must be supported by evidence.
* The VA/DoD Guideline Champions will reply to the respondents and will integrate comments and suggestions into the evidence review as appropriate.

12. An executive panel of the guideline work group re-convenes to finalize the guideline and identify the content of the provider education tools:

* The executive panel will be reconvened to integrate the comments of the reviewers, as appropriate, and to complete the guideline.
* At this same face-to-face meeting, the group will also begin to identify the components of the guideline summary, pocket card, health tips and performance measures that could be used to assess guideline implementation and outcomes.
* Emphasis will be placed to assure that level of evidence for the recommendations captured in the pocket card, and/or health tips, etc. is identified on the printed materials.
* All guideline modules must contain the date of the last systematic evidence review.

**Step 13: There are 2 Steps in the Review of the Final Guideline Draft:**

**13 A: The Final Draft of the Guideline is posted on the web for review and public comment:**

* This portion of the review is directed towards an **evaluation of the content** of the recommendation, **the logic of the algorithm,** and the **format and usability** of the guideline.
* Comments and recommendations regarding proposed changes to the content of the guideline must be supported by evidence.
* A summary of the comments and suggestions collected through the web page will be sent to the champion/executive panel of the working group

**13 B:** **The Final Draft is then submitted for Independent Review:**

* The final draft of the guideline is assigned to at least three VA /DoD staff or outside national experts who have been trained in the review of scientific literature and have agreed to perform an independent review of each guideline.
* This independent review is directed towards an **evaluation of the content** of the guideline, as well as the **format and usability** of the guideline.
* The rating tool containing the reviewer’s comments and recommendations will be forwarded to the Office of Quality, Safety & Value. Major issues are forwarded to the EBPWG as needed. (See Attachment III)
* The reviewer’s comments and recommendations regarding the content of the guideline will be provided to the champions / the executive panel of the working group.

**14. Final Editing Incorporates Feedback as Appropriate:**

* The Champion(s), in consultation with key experts from the editorial panel of the guideline, and the facilitator will integrate the comments and suggestions into the final document as appropriate. **This includes the guideline summary and provider education tools.**
* Discussion of serious controversies regarding interpretation of the evidence will be included in the introduction to the guideline and may be the subject of discussion at the time of review with the EBPWG.

**15. The Final Guideline, Tools, and Comments from Independent Review are Submitted to VA/DoD Evidence Based Practice Workgroup Subgroup for Review**:

* The VA/DoD EBPWG again reviews comments from independent reviewers and verifies that all appropriate suggestions have been incorporated into the final document.
* An electronic copy of the guideline along with a summary of the comments from the reviewers will be provided to the entire VA/DoD EBPWG at least two weeks in advance of the meeting.

**16. Presentation of Guideline to full VA/DoD EBPWG for Approval:**

* When the EBPWG is convened, the Champion(s), and the Evidence Chaperone if utilized, will present the guideline to the EBPWG and recommend endorsement for implementation throughout VA and DoD.
* The Champion(s) will hear the deliberations of the EBPWG and will be provided feedback that will be entered into the minutes of the EBPWG.
* The Guideline will then be either endorsed or further modifications will be made.
* When endorsed, Employee Education System will put the tools into final format.

**17. The Guideline and Other Related Tools are Posted on the Office of Quality and Performance internet and intranet and the DoD internet sites**

**DoD Internet:** [**https://www.qmo.amedd.army.mil/pguide.htm**](https://www.qmo.amedd.army.mil/pguide.htm)

**VA Internet:** [**http://www.healthquality.va.gov/**](http://www.healthquality.va.gov/)

**VA Intranet:** <http://vaww.oqsv.med.va.gov/functions/mindfulness/cp/clinicalPractic.aspx>.

All guidelines placed on the Web will conform to the requirements described in Section 508 of the Rehabilitation Act of 1973, as amended. 29 U.S.C. §798 (see http://www.access-board.gov/sec508/guide/act.htm

1. **Guideline Update and Approval Process:**

**Evidence Based Practice Work Group Approves Schedule for Update of Clinical Practice Guidelines:** The immediate update of guidelines will be triggered if any recommendation contained in a guideline is identified as harmful to patients (i.e., pharmaceutical or device recall, etc.) Routine guideline updates will ideally occur every three to five years. The process that will be followed mirrors that of guideline development.

It is recognized that there may be areas of significant evidence advancement in between update periods. Guideline champions may bring focused update requests forward to the EBPWG at anytime for consideration.

* EBPWG considers request for focused update.
* If approved, then convene a small work group consisting of the champions and 1-2 subject matter experts.
* Focused evidence review (typically limited to Medline, Cochrane library, meeting proceedings).
* Results and recommendations from the focused review will be presented to the EBPWG for approval.
* Once approved by EBPWG results will be posted to the electronic version of the CPG as an addendum.
* CPG focused update will be posted to National Guideline Clearinghouse.

\*Harris RP, Helfand M, Woolf SH, Current methods of the U.S. Preventive Services Task Force. A review of the process. Am J Prev Med 2001

Martinez-Garcia, L, Arevalo-Rodriguez, I., Sola, I., Haynes, RB, Vandvik, PO, et.al. Strategies for monitoring and updating clinical practice guidelines: a systematic review. Implementation Science, 2012

Attachment I - Guideline Project Submission Form

VA/DoD Evidence-Based Clinical Practice Guidelines

**Guideline Project Submission Form**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Project Name** | | | | | | | |
| **Project Description** | | | | | | | |
| **Project Champion** | | | | | | | |
| **Last Name** | | | **First Name** | | | | **Title** |
| **Service/Organization/Command** | | |  | | | | |
| **Address** |  | | | | | | |
| **City** | | | | **State** | | **Zip Code** | |
| **Phone** | | **Fax** | | | **E-mail** | | |

**MAKING A CASE FOR CHANGE** – Provide narrative to support guideline development.

***Perceived gap in health status:***

[Is there new information from the medical literature? What about current outcomes (e.g., prevalent conditions, diagnosis)? Are there clinical areas for improvement suggested by clinicians? Are there benchmarks available that suggest a need to change practice? Are there existing evidence-based guidelines on this subject? What is the impact of this guideline on patient outcomes?]

***Perceived gap in patient satisfaction:***

[Is there survey information available addressing patient satisfaction that indicates an opportunity for improvement? Are there benchmarks available that suggest a need to change practice?]

***Perceived gap in provider satisfaction:***

[Are there surveys or suggestions addressing provider satisfaction that indicate an opportunity for improvement? Are there benchmarks available that suggest a need to change practice?]

***Perceived gap in cost/utilization:***

[Are there areas of care with high utilization? Is there significant variation or an opportunity for improvement in utilization patterns (e.g. drug utilization, lab utilization, referral rates, or local variation)? Are there benchmarks available that suggest a need to change practice? Rational and supporting evidence of relevance/importance of topic to the VA and/or DoD population?]

***Perceived organizational issues:***

[Are there political or organizational reasons why a change in practice might be warranted? Are there benchmarks available that suggest a need to change practice? Is the implementation of this project feasible? Is there evidence available to support evidence-based guideline development?]

Attachment II –VA/DoD Evidence-Based Clinical Practice Guideline Workgroup

DISCLOSURE STATEMENT

VA/DoD Evidence-Based Clinical Practice Guideline Workgroup

**DISCLOSURE STATEMENT**

The VA/DoD Evidence-Based Clinical Practice Guideline (EBCPG) Workgroup members (voting and non-voting), as well as developers, reviewers, and others involved in the clinical practice guideline (CPG) process, are asked to sign a disclosure statement annually to detail involvement, of any kind, with manufacturers that may benefit from the inclusion or recommendation of their products within a VA/DoD CPG. This includes, but is not limited to, pharmaceuticals, diagnostic products/equipment, and monitoring supplies.

Please list the various projects you are involved with over the past two years in regards to the following areas:

|  |  |  |  |
| --- | --- | --- | --- |
| 1 | Do you participate in research funded by pharmaceutical manufacturers? | YES | NO |
|  | If YES, please list the company(ies), product(s), or disease  state(s): | | |
| 2 | Do you serve on a Speakers Bureau? | YES | NO |
|  | If YES, please list the company(ies), product(s), or disease  state(s): | | |
| 3 | Do you receive remuneration for activities (such as board member or member of an advisory council) for any company or product that is coming to market? | YES | NO |
|  | If YES, please list the company(ies), product(s), or disease  state(s): | | |
| 4 | Do you have financial holdings (to include, but not limited to, company stock, bonds, or other shares, etc.) of said companies and/or products? | YES | NO |
|  | If YES, please list the company(ies), product(s), or fund(s): | | |

***I affirm, to the best of my knowledge, the above statement is inclusive of my functions with said product(s), company(ies), and disease state(s). I acknowledge that if my involvement changes, I am to contact the respective VA or DoD EBCPG Workgroup co-chair and update this disclosure form immediately. I will recuse myself from voting on guideline selection, development, adaptation, or tool kit development matters concerning issues where a conflict of interest (or appearance of a conflict of interest) may exist.***

SIGNATURE \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ DATE\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Printed Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Attachment III-External Reviewer Form

**VA/DoD CLINICAL PRACTICE GUIDELINES**

**(Guideline Rating Tool 4-1-2010)**

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**Reviewer\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Date\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Title of the Guideline\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Do you have any conflict of interest or potential conflict of interest in reviewing this guideline?

**No**  **Yes**  **(Specify if yes.)** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| A. SCOPE AND PURPOSE | Strongly  Agree | Agree | Disagree | Strongly  Disagree |
| 1. Targeted patient population is specified. |  |  |  |  |
| 2. Intended users of guideline are specified. |  |  |  |  |
| 3. Guideline addresses a documented gap in performance, safety, or quality. |  |  |  |  |
| COMMENTS | | | | |
|  | | | | |
|  | | | | |
|  | | | | |
| B1. PRESENTATION | Strongly  Agree | Agree | Disagree | Strongly  Disagree |
| 4. The guideline is clearly written. |  |  |  |  |
| 5. Guideline defines unfamiliar terms and those that are critical to applying the recommendations. |  |  |  |  |
| 6. The recommendations are specific and unambiguous. |  |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **B2. PRESENTATION** | Strongly  Agree | Agree | Disagree | Strongly |
| 7**.** The algorithm is logically complete and internally consistent. |  |  |  |  |
| COMMENTS | | | | |
|  | | | | |
|  | | | | |
|  | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **C1. SYSTEMATIC REVIEW METHODS** | Strongly Agree | Agree | Disagree | Strongly Disagree |
| 8. Systematic methods were used to search for evidence. |  |  |  |  |
| 9. The criteria for selecting the evidence are clearly described. |  |  |  |  |
| 1. The quality of the studies was explicitly assessed. |  |  |  |  |
| **C2. SYSTEMATIC REVIEW METHODS** | YES | NO | NOT  SURE |  |
| 11. Eligible studies were summarized in evidence tables. |  |  |  |  |
| **COMMENTS** | | | | |
|  | | | | |
|  | | | | |
|  | | | | |
| **D. INTERGRATING EVIDENCE INTO RECOMMENDATIONS** | Strongly  Agree | Agree | Disagree | Strongly  Disagree |
| 12. The methods used to formulate the recommendations are clearly described? |  |  |  |  |
| 13. There is an explicit link between the recommendations and the supporting evidence. |  |  |  |  |
| 14. Was sufficient information provided to understand the rationale behind key or controversial recommendations? |  |  |  |  |
| **COMMENTS (on D. Integrating the Evidence)** | | | | |
|  | | | | |
|  | | | | |
|  | | | | |
| **E. BENEFITS, HARMS AND OUTCOMES** | Strongly  Agree | Agree | Disagree | Strongly  Disagree |
| 15. All important benefits and harms of recommended treatments or procedures are specified. |  |  |  |  |
| 16. Benefits and harms of recommended treatments and procedures are quantified. |  |  |  |  |
| 17. The effect of the recommended interventions on health care costs is quantified. |  |  |  |  |
| COMMENTS | | | | |
|  | | | | |
|  | | | | |
|  | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| F. AUTHORSHIP | Strongly Agree | Agree | Disagree | Strongly  Disagree |
| 18. The guideline clearly notes author(s). |  |  |  |  |
| 19. The guideline clearly notes the authors’ conflicts of interest. |  |  |  |  |
| 20. All relevant disciplines are represented including primary care? |  |  |  |  |
| **COMMENTS** | | | | |
|  | | | | |
|  | | | | |
|  | | | | |
| G. TESTING AND REVIEW | Strongly  Agree | Agree | Disagree | Strongly  Disagree |
| 21. The guideline has been evaluated by field testing. |  |  |  |  |
| 22. An expiration date or procedure for updating the guideline is specified. |  |  |  |  |
| **COMMENTS** | | | | |
|  | | | | |
|  | | | | |
|  | | | | |
| H. FLEXIBILITY | Strongly  Agree | Agree | Disagree | Strongly  Disagree |
| 23. The guideline clearly indicates the intended flexibility of the recommendation(s). |  |  |  |  |
| 24. The role of patient preferences is discussed. |  |  |  |  |
| 25. The guideline addresses special patient populations when appropriate. |  |  |  |  |
| **COMMENTS** | | | | |
|  | | | | |
|  | | | | |
|  | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **I. FEASIBILITY OF IMPLEMENTING THE GUIDELINE** | Strongly  Agree | Agree | Disagree | Strongly  Disagree |
| 26. The guideline recommendations are feasible to implement in all intended care settings (consider organizational characteristics, implementation costs, opportunity costs.) |  |  |  |  |
| **COMMENTS** | | | | |
|  | | | | |
|  | | | | |
|  | | | | |

# OVERALL ASSESSMENT

**27. Describe the predominant method(s) used to develop this guideline:**

**Evidence-based (key recommendations are supported by fair or good evidence with explicit estimation of benefits and harms)**

Evidence-based (all recommendations are supported by fair or good evidence)

**Structured consensus with systematic literature reviews**

**Global subjective judgment or consensus panel**

**Other (describe) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**28. Would you recommend these guidelines for use in practice?**

**STRONGLY RECOMMEND**

**RECOMMEND**

**WOULD NOT RECOMMEND**

**UNSURE**

**COMMENT: (What is this guideline’s specific strengths? What is this guideline’s specific weaknesses? Use additional space as necessary.)**

|  |
| --- |
|  |
|  |
|  |
|  |

**Additional Review Comments: How can/might this guideline be improved?**

|  |
| --- |
|  |
|  |
|  |
|  |

**Name of Reviewe**r **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Address**\_**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Phone** \_**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**E-Mail** \_**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

***VHA, Office of Quality & Performance, Evidence Review Subgroup, 2010***